EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( [email protected] ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-sol/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
View source version on businesswire.com:https://www.businesswire.com/news/home/20250620207625/en/
CONTACT: Kahn Swick & Foti, LLC
Lewis S. Kahn
[email protected]
855-768-1857
1100 Poydras St., Suite 960
New Orleans, LA 70163
KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA
INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL
SOURCE: Kahn Swick & Foti, LLC
Copyright Business Wire 2025.
PUB: 06/20/2025 08:51 PM/DISC: 06/20/2025 08:50 PM
http://www.businesswire.com/news/home/20250620207625/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 minutes ago
- Bloomberg
Bloomberg Business of Sports: A Dark Day for NYC, NFL
Join hosts Michael Barr, Damian Sassower and Vanessa Perdomo for a look at some of the latest headlines and stories in the business of sports. The former football player who fatally shot four people and himself in Midtown Manhattan claimed to have a poorly understood brain disease, putting a renewed focus on the link between head injuries in sports and irreversible brain damage. Shane Tamura was targeting the National Football League's headquarters when he entered 345 Park Avenue, a skyscraper that's also home to offices of private equity giant Blackstone Inc. and consultant KPMG. One NFL employee was injured in the shooting. In 2015, the league reached a $765 million settlement with over 4,500 players who claimed in a lawsuit that the NFL had hidden the dangers of concussions. The league denied any wrongdoing. Years after the settlement, the NFL is still grappling with issues related to head injuries. Bloomberg US sports business reporter Randall Williams joins to discuss his reporting on the aftermath of the shooting and why getting answers on CTE has proven so difficult for the NFL. Also on this week's show: Bloomberg News global business reporter Ira Boudway on the WNBA's growth Morgan Shaw Parker, President and Chief Operating Officer for the WNBA's Atlanta Dream about her team's recent success and growth.
Wall Street Journal
9 minutes ago
- Wall Street Journal
Heard on the Street Recap: Jobs Stall
The Dow Jones Industrial Average turned in its worst week since April. (Michael Nagle/Bloomberg News)
Yahoo
an hour ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
